Full Press Release Details
Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025.
LXRX
Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
Key Takeaway: Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
Price reaction · baseline $0.2926 (2025-03-03 close) · hit after-hours · 2 other LXRX headline(s) in the window, move may be shared
day 0 close
+11%
day 1
+14.8%
day 3 · peak
+33.9%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+111%
120-day peak, hindsight
Typical move
11%
average across 13 past catalysts
Cash runway
~61 mo
Minimal dilution risk
Lead asset
Sotagliflozin
Phase 3 · Type 1 Diabetes Mellitus